San­thera kicks idebenone DMD pro­gram to the curb af­ter PhI­II tri­al fails in­ter­im analy­sis

An oft-trou­bled pro­gram at San­thera Phar­ma­ceu­ti­cals {SWX: $SANN} is head­ed for the chop­ping block.

The Swiss biotech an­nounced Tues­day morn­ing that it is dis­con­tin­u­ing a Phase III study for idebenone in pa­tients with Duchenne mus­cu­lar dy­s­tro­phy and re­ceiv­ing steroid treat­ment. In a re­lease, San­thera said that the tri­al failed an in­ter­im analy­sis, and as a re­sult will pull its EMA ap­pli­ca­tion and end glob­al de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER